Valuation: Senzime AB

Market Cap 431M 43.8M 38.19M 35.97M 32.76M 61.42M 4.2B 61.49M 166M 2.14B 165M 161M 6.9B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 431M 43.8M 38.19M 35.97M 32.76M 61.42M 4.2B 61.49M 166M 2.14B 165M 161M 6.9B EV / Sales 2026 *
3.37x
EV / Sales 2027 * 2.11x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -
1 day-3.45%
1 week-19.79%
Current month-30.00%
1 month-28.21%
3 months-41.49%
6 months-43.85%
Current year-48.35%
1 week 0.28
Extreme 0.28
0.31
1 month 0.28
Extreme 0.28
0.4
Current year 0.28
Extreme 0.28
0.62
1 year 0.28
Extreme 0.28
0.65
3 years 0.28
Extreme 0.28
0.96
5 years 0.25
Extreme 0.251
2.45
10 years 0.25
Extreme 0.251
3
Manager TitleAgeSince
Chief Executive Officer 53 2023-05-02
Director of Finance/CFO 56 2021-12-31
Chief Tech/Sci/R&D Officer 50 2022-12-31
Director TitleAgeSince
Chairman 53 2023-05-02
Director/Board Member 70 2015-12-31
Director/Board Member 63 2020-03-04
Change 5-day change 1-year change 3-year change Capi.($)
-3.45%-19.79% - - 46.23M
+0.36%-0.11%-24.30%+4.09% 178B
-0.41%-2.19%-3.50%+14.03% 118B
+2.50%-2.99%+9.13%+71.14% 58.92B
-0.13%-1.21%-3.39%-31.82% 49.29B
-0.22%+0.78%+10.27%+47.46% 48.17B
-0.20%+5.30%+32.20%+0.10% 33.72B
+1.01%-1.93% - - 27.76B
-0.15%+1.85%+41.96%-3.34% 25.5B
+1.77%+9.57%+8.39%-13.10% 22.1B
Average +0.11%+1.19%+8.84%+11.07% 62.32B
Weighted average by Cap. +0.36%-0.14%-2.85%+12.98%

Financials

2026 *2027 *
Net sales 128M 12.98M 11.32M 10.66M 9.71M 18.21M 1.24B 18.23M 49.22M 634M 48.77M 47.69M 2.04B 204M 20.74M 18.09M 17.03M 15.51M 29.08M 1.99B 29.12M 78.63M 1.01B 77.92M 76.19M 3.27B
Net income -68.9M -7.01M -6.11M -5.75M -5.24M -9.82M -671M -9.84M -26.56M -342M -26.32M -25.73M -1.1B -36.8M -3.74M -3.26M -3.07M -2.8M -5.25M -358M -5.25M -14.18M -183M -14.06M -13.74M -589M
Net Debt - -
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume
26-09-21 US$0.2800 -3.45% 1,000
26-09-18 US$0.2900 -6.45% 2,500
26-09-17 US$0.3100 -7.46% 15,000

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!